Lexicon Genetics Grants Non-Exclusive Sublicense to Eli Lilly and Company

Strategic Insights -

Lexicon Genetics, a leader in defining the functions of genes for drug discovery, has granted a non-exclusive sublicense to Eli Lilly and Company, allowing the latter to use certain aspects of Lexicon's gene-targeting technology in its internal drug discovery and target validation programs. This collaboration is the latest in a growing list of sublicensees for Lexicon's technology, which has become the gold standard for target validation. With this agreement, Lexicon solidifies its position as a pioneer in the field of functional genomics, with its technologies being used to accelerate large-scale analysis of mammalian gene function for drug discovery.

Key Takeaways:

  • Lexicon Genetics has granted a non-exclusive sublicense to Eli Lilly and Company for the use of certain aspects of its positive-negative selection and isogenic DNA technologies.
  • The sublicense will be used by Lilly in its internal drug discovery and target validation programs.
  • This is the eleventh organization to access Lexicon's technology, which has become the gold standard for target validation.
  • Lexicon's technologies are used to target genes for the generation of knockout mice, which are used to determine the role of specific genes in mammalian disease and physiology.
  • Lexicon holds exclusive rights to patents that cover positive-negative selection technology and isogenic DNA technology.
  • The company has invented high-throughput genome-wide gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of knockout mouse clones.
  • Lexicon uses an integrated platform of functional genomics technologies to accelerate large-scale analysis of mammalian gene function for drug discovery.
  • The company has collaborations with leading pharmaceutical and academic institutions worldwide.

Statistics:

  • 11 organizations have accessed Lexicon's technology.
  • Lexicon has invented high-throughput genome-wide gene trapping technology.
  • The company's OmniBank library contains tens of thousands of knockout mouse clones.
  • Axion is one of the leading companies that has participated in collaborations with leading pharmaceutical and academic institutions worldwide.
  • Lexicon has over 100 collaborations and partnerships with pharmaceutical companies.

Sources:

  • Lexicon Genetics, Inc. (The Woodlands, TX; 281-364-0100)
  • Eli Lilly and Company (Indianapolis, IN; 317-261-2000)
  • United States Patents 5,464,764, 5,487,992, 5,627,059, and 5,631,153
  • United States Patent 5,789,215